Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joyce S Plested

Showing results (11-20 of 50) with videos related to

Pageof 5
Sort By:
Microorganisms|March 28, 2024
A Pseudovirus-Based Neutralization Assay for SARS-CoV-2 Variants: A Rapid, Cost-Effective, BSL-2-Based High-Throughput Assay Useful for Vaccine Immunogenicity EvaluationZhaohui Cai, Raj Kalkeri, Mingzhu Zhu, et al.
Vaccine|April 4, 2025
Immunogenicity and safety of a monovalent Omicron XBB.1.5 SARS-CoV-2 recombinant spike protein vaccine in previously unvaccinated, SARS-CoV-2 seropositive participants: Primary day-28 analysis of a phase 2/3 open-label studyKatia Alves, Alex Kouassi, Joyce S Plested, et al.
Vaccine|December 27, 2025
Safety and immunogenicity of a single dose of a JN.1 variant COVID-19 vaccine in previously vaccinated adults: Primary analysis report of a phase 3 open-label trialKatia Alves, Alex Kouassi, Joy Nelson, et al.
Vaccine|October 7, 2008
Naturally-occurring human serum antibodies to inner core lipopolysaccharide epitopes of Neisseria meningitidis protect against invasive meningococcal disease caused by isolates displaying homologous inner core structuresAnne Jäkel, Joyce S Plested, J Claire Hoe, et al.
Infection and Immunity|December 23, 2003
Development, characterization, and functional activity of a panel of specific monoclonal antibodies to inner core lipopolysaccharide epitopes in Neisseria meningitidisMargaret Anne J Gidney, Joyce S Plested, Suzanne Lacelle, et al.
Microorganisms|June 27, 2024
Validation of a Pseudovirus Neutralization Assay for Severe Acute Respiratory Syndrome Coronavirus 2: A High-Throughput Method for the Evaluation of Vaccine ImmunogenicityZhaohui Cai, Raj Kalkeri, Mi Wang, et al.
Vaccine|January 17, 2026
Immunogenicity and safety of a recombinant spike protein COVID vaccine in patients with inflammatory bowel disease and transplant recipientAhamed Lazim Vattoth, Mary S Hayney, Amir Masoud Forati, et al.
The Journal of Infectious Diseases|April 16, 2003
Highly conserved Neisseria meningitidis inner-core lipopolysaccharide epitope confers protection against experimental meningococcal bacteremiaJoyce S Plested, Shannon L Harris, J Claire Wright, et al.
Medrxiv : the Preprint Server for Health Sciences|May 22, 2023
Immunogenicity of NVX-CoV2373 in PREVENT-19: A Phase 3, Randomized, Placebo-Controlled Trial in Adults in the United States and MexicoGermán Áñez, Karen L Kotloff, Cynthia L Gay, et al.
The Journal of Allergy and Clinical Immunology|March 28, 2025
Immunogenicity of adjuvanted recombinant SARS-CoV-2 spike protein vaccine after earlier mRNA vaccine dosesJeffrey M Adelglass, Paul Bradley, Miranda R Cai, et al.
Pageof 5

Showing results (11-20 of 50) with videos related to

Sort By:
Pageof 5
Microorganisms|March 28, 2024
A Pseudovirus-Based Neutralization Assay for SARS-CoV-2 Variants: A Rapid, Cost-Effective, BSL-2-Based High-Throughput Assay Useful for Vaccine Immunogenicity EvaluationZhaohui Cai, Raj Kalkeri, Mingzhu Zhu, et al.
Vaccine|April 4, 2025
Immunogenicity and safety of a monovalent Omicron XBB.1.5 SARS-CoV-2 recombinant spike protein vaccine in previously unvaccinated, SARS-CoV-2 seropositive participants: Primary day-28 analysis of a phase 2/3 open-label studyKatia Alves, Alex Kouassi, Joyce S Plested, et al.
Vaccine|December 27, 2025
Safety and immunogenicity of a single dose of a JN.1 variant COVID-19 vaccine in previously vaccinated adults: Primary analysis report of a phase 3 open-label trialKatia Alves, Alex Kouassi, Joy Nelson, et al.
Vaccine|October 7, 2008
Naturally-occurring human serum antibodies to inner core lipopolysaccharide epitopes of Neisseria meningitidis protect against invasive meningococcal disease caused by isolates displaying homologous inner core structuresAnne Jäkel, Joyce S Plested, J Claire Hoe, et al.
Infection and Immunity|December 23, 2003
Development, characterization, and functional activity of a panel of specific monoclonal antibodies to inner core lipopolysaccharide epitopes in Neisseria meningitidisMargaret Anne J Gidney, Joyce S Plested, Suzanne Lacelle, et al.
Microorganisms|June 27, 2024
Validation of a Pseudovirus Neutralization Assay for Severe Acute Respiratory Syndrome Coronavirus 2: A High-Throughput Method for the Evaluation of Vaccine ImmunogenicityZhaohui Cai, Raj Kalkeri, Mi Wang, et al.
Vaccine|January 17, 2026
Immunogenicity and safety of a recombinant spike protein COVID vaccine in patients with inflammatory bowel disease and transplant recipientAhamed Lazim Vattoth, Mary S Hayney, Amir Masoud Forati, et al.
The Journal of Infectious Diseases|April 16, 2003
Highly conserved Neisseria meningitidis inner-core lipopolysaccharide epitope confers protection against experimental meningococcal bacteremiaJoyce S Plested, Shannon L Harris, J Claire Wright, et al.
Medrxiv : the Preprint Server for Health Sciences|May 22, 2023
Immunogenicity of NVX-CoV2373 in PREVENT-19: A Phase 3, Randomized, Placebo-Controlled Trial in Adults in the United States and MexicoGermán Áñez, Karen L Kotloff, Cynthia L Gay, et al.
The Journal of Allergy and Clinical Immunology|March 28, 2025
Immunogenicity of adjuvanted recombinant SARS-CoV-2 spike protein vaccine after earlier mRNA vaccine dosesJeffrey M Adelglass, Paul Bradley, Miranda R Cai, et al.
Pageof 5